What is the additional mean IOP reduction for topical carbonic anhydrase inhibitors (CAIs)?

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

What is the additional mean IOP reduction for topical carbonic anhydrase inhibitors (CAIs)?

Explanation:
Topical carbonic anhydrase inhibitors lower IOP by reducing aqueous humor production in the ciliary body through inhibition of carbonic anhydrase, which decreases bicarbonate formation and ion transport. When added to a treatment regimen, they typically provide an additional mean IOP reduction of about three millimeters of mercury. That around-three mmHg effect is the expected average across many patients, though individual responses can vary. These agents are useful as an adjunct when more lowering is needed, and they’re generally well tolerated, with potential local eye symptoms or rare sulfa-related concerns rather than systemic effects.

Topical carbonic anhydrase inhibitors lower IOP by reducing aqueous humor production in the ciliary body through inhibition of carbonic anhydrase, which decreases bicarbonate formation and ion transport. When added to a treatment regimen, they typically provide an additional mean IOP reduction of about three millimeters of mercury. That around-three mmHg effect is the expected average across many patients, though individual responses can vary. These agents are useful as an adjunct when more lowering is needed, and they’re generally well tolerated, with potential local eye symptoms or rare sulfa-related concerns rather than systemic effects.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy